Pharmaceutical

Gilead acquires CymaBay Therapeutics for $4.3bn

Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.

Mar 26, 2024 - 00:00
Gilead acquires CymaBay Therapeutics for $4.3bn
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.
Read the original article

Tags:

Previous Article

Birmingham University to develop lollipop for mouth cancer detection

Next Article

FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CDC and social media: The new misinformation war

CDC and social media: The new misinformation war

Feb 7, 2024

Morning Rounds: Americans put faith in nurses as overall confidence in health care ebbs

Morning Rounds: Americans put faith in nurses as overal...

Dec 21, 2023

FDA oversees rise in awarded orphan drug designations for myelofibrosis

FDA oversees rise in awarded orphan drug designations f...

Nov 14, 2023